Physician profile
James Robert Bailey
NPI 1144584905
$3,197.59
in general payments reported to CMS, 2019-2025
26 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $618 · 2021: $231 · 2022: $402 · 2023: $638 · 2024: $530 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Education: $23.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,721.34 |
| Education | $23.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.40 | 2019-2025 | Durysta, Skyrizi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.61 | 2019-2021 | |
| Janssen Biotech, INC. | $261.35 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $225.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.12 | 2019-2022 | |
| Celgene Corporation | $190.36 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $92.14 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $81.53 | 2020-2023 | |
| Depuy Synthes Sales INC. | $79.30 | 2019 | |
| Romark Laboratories, Lc | $66.70 | 2019-2020 | |
| Lilly USA, LLC | $53.83 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $50.11 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $49.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $45.47 | 2025 | Vowst, Zenpep |
| Regeneron Healthcare Solutions, INC. | $34.11 | 2024 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33.60 | 2025 | Hadlima, Renflexis |
| Celltrion USA INC. | $23.70 | 2024 | Zymfentra |
| Pfizer INC. | $20.93 | 2020 | |
| Ferring Pharmaceuticals INC. | $16.88 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $16.40 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.36 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $14.86 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $14.14 | 2020 | |
| Intercept Pharmaceuticals, INC. | $12.70 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2020 | |
| Redhill Biopharma INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.